focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Regulatory News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,364.00
Bid: 11,850.00
Ask: 12,470.00
Change: 0.00 (0.00%)
Spread: 620.00 (5.232%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 12,364.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Result of External Audit Tender

23 Dec 2015 16:30

RNS Number : 0932K
AstraZeneca PLC
23 December 2015
 



Result of the External Audit Tender

AstraZeneca PLC (the Company) today announced a proposal to appoint PricewaterhouseCoopers LLP (PwC) as its external auditor for the financial year ending 31 December 2017.

As disclosed in the Company's Annual Report, the Audit Committee determined that the audit would be put out to tender by 2018 in accordance with the transitional guidance issued by the Financial Reporting Council. The proposed change of auditor follows a recommendation by the Audit Committee to the Board based on a formal tender in line with best practice. Further information on the tender process will be provided in the Audit Committee Report contained in the Company's Annual Report for the financial year ending 31 December 2015.

A resolution to approve the appointment of PwC will be put to shareholders at the Company's AGM in 2017.

A resolution to re-appoint the Company's current auditor, KPMG LLP, for the financial year ending 31 December 2016 will be put to shareholders at the Company's AGM in 2016.

KPMG has been the auditor of the AstraZeneca Group since the merger of Astra and Zeneca in 1999 and the Board would like to thank KPMG for its years of service to the Company.

 

23 December 2015

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCBLBDDUGDBGUX
Date   Source Headline
28th May 20217:00 amRNSTagrisso approved in EU in early lung cancer
27th May 20214:41 pmRNSSecond Price Monitoring Extn
27th May 20214:36 pmRNSPrice Monitoring Extension
27th May 20217:00 amRNSAstraZeneca prices a EUR800m bond offering
26th May 20219:24 amRNSStabilisation Notice
26th May 20217:00 amRNSAstraZeneca prices a $7bn bond offering
25th May 20217:00 amRNSEMTN programme update - publication of Prospectus
21st May 20217:00 amRNSVaxzevria COVID-19 vaccine approved in Japan
18th May 20213:30 pmRNSDirector/PDMR Shareholding
11th May 20212:00 pmRNSResult of AGM
11th May 20211:55 pmRNSShareholders vote in favour of Alexion acquisition
7th May 20217:00 amRNSImfinzi + tremelimumab showed survival in POSEIDON
5th May 20216:30 pmRNSHolding(s) in Company
4th May 20213:00 pmRNSTotal Voting Rights
4th May 20217:00 amRNSFarxiga approved in the US for CKD
30th Apr 20217:00 amRNSAZN: First quarter 2021 results
26th Apr 20217:10 amRNSSelumetinib recommended for EU approval in NF1
26th Apr 20217:05 amRNSTagrisso adjuvant receives positive CHMP opinion
26th Apr 20217:00 amRNSNirsevimab Phase III trial met primary endpoint
16th Apr 202112:00 pmRNSUS clearance of proposed acquisition of Alexion
14th Apr 20217:00 amRNSTagrisso approved in China in early lung cancer
12th Apr 20211:00 pmRNSCircular and notice of general meeting
12th Apr 20217:00 amRNSUpdate on Farxiga COVID-19 DARE-19 Phase III trial
1st Apr 20213:00 pmRNSTotal Voting Rights
30th Mar 202112:15 pmRNSNotice of AGM
25th Mar 20213:00 pmRNSDirector/PDMR Shareholding
25th Mar 20217:00 amRNSAZD1222 US Ph3 primary analysis confirms efficacy
22nd Mar 20217:00 amRNSAstraZeneca US vaccine trial met primary endpoint
16th Mar 20217:05 amRNSDivestment of Viela shareholding completed
16th Mar 20217:00 amRNSUS supply agreement for additional AZD7442 doses
9th Mar 20213:00 pmRNSDirector/PDMR Shareholding
4th Mar 20213:00 pmRNSDesignation of EU home member state
3rd Mar 20217:00 amRNSUS court decision favours Symbicort patents
2nd Mar 20217:00 amRNSFurther update on roxadustat US regulatory review
1st Mar 20213:00 pmRNSTotal Voting Rights
22nd Feb 20217:00 amRNSVoluntary withdrawal Imfinzi US bladder indication
17th Feb 20217:00 amRNSLynparza: IDMC recommend early analysis of OlympiA
16th Feb 202111:15 amRNSFiling of Form 20-F with SEC
15th Feb 20213:00 pmRNSDirector/PDMR Shareholding
15th Feb 202111:00 amRNSAnnual Financial Report
11th Feb 20217:01 amRNSAstraZeneca Non-Executive Board changes
11th Feb 20217:00 amRNSAZN: full-year 2020 results
10th Feb 20217:00 amRNSDivestment of Crestor in Europe completed
5th Feb 20217:00 amRNSUpdate on KESTREL Phase III trial for Imfinzi
4th Feb 20217:00 amRNSForxiga approved in China for heart failure
1st Feb 20213:00 pmRNSTotal Voting Rights
1st Feb 202112:15 pmRNSAstraZeneca agrees to divest Viela shareholding
1st Feb 20217:00 amRNSCOVID-19 vaccine authorised for use by the EU
29th Jan 20213:16 pmRNSCOVID-19 vaccine receives positive opinion in EU
26th Jan 20213:00 pmRNSBlock listing application

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.